Sargent Bickham Lagudis LLC Moderna, Inc. Transaction History
Sargent Bickham Lagudis LLC
- $1.22 Billion
- Q4 2022
A detailed history of Sargent Bickham Lagudis LLC transactions in Moderna, Inc. stock. As of the latest transaction made, Sargent Bickham Lagudis LLC holds 786 shares of MRNA stock, worth $30,064. This represents 0.01% of its overall portfolio holdings.
Number of Shares
786
Previous 686
14.58%
Holding current value
$30,064
Previous $81,000
74.07%
% of portfolio
0.01%
Previous 0.01%
Shares
10 transactions
Others Institutions Holding MRNA
# of Institutions
952Shares Held
241MCall Options Held
10.6MPut Options Held
18.7M-
Baillie Gifford & CO42.5MShares$1.62 Billion2.17% of portfolio
-
Vanguard Group Inc Valley Forge, PA40.2MShares$1.54 Billion0.05% of portfolio
-
Black Rock Inc. New York, NY25.6MShares$978 Million0.07% of portfolio
-
State Street Corp Boston, MA16.8MShares$644 Million0.05% of portfolio
-
Theleme Partners LLP London, X07.23MShares$276 Million28.47% of portfolio
About Moderna, Inc.
- Ticker MRNA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 391,200,000
- Market Cap $15B
- Description
- Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, resp...